Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis
The results of this study suggest that compared with other anti-IL mAb therapies for the treatment of moderate-to-severe AD, nemolizumab has similar efficacy in achieving EASI-75 and IGA success, and a comparable safety profile. This is in addition to nemolizumab's well-demonstrated efficacy in improving itch. Nemolizumab may be particularly beneficial in clinical settings where patients and physicians are seeking to manage AD with a well-tolerated therapeutic.
Authors
- Jorge Puelles (ORCID: https://orcid.org/0000-0003-3493-1252)
- Sofia Schiavo
- Ramkumar Subramanian (ORCID: https://orcid.org/0009-0001-0060-9540)
- Liliana Ulianov (ORCID: https://orcid.org/0009-0001-2897-6895)
- Andrew Pink
- John Houghton
- Rajesh Rout
- Katrin Jack (ORCID: https://orcid.org/0009-0006-0814-2427)
- Christophe Piketty
- Holly White
Institutions
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Galderma (Switzerland) (CH)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1007/s13555-025-01647-0
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Celgene
- Galderma
- LEO Pharma